View Future GrowthS.C. Ropharma 過去の業績過去 基準チェック /26S.C. Ropharmaの収益は年間平均-35.2%の割合で減少していますが、 Consumer Retailing業界の収益は年間 減少しています。収益は年間15.7% 13.1%割合で 増加しています。 S.C. Ropharmaの自己資本利益率は2.6%であり、純利益率は0.1%です。主要情報-35.16%収益成長率-36.41%EPS成長率Consumer Retailing 業界の成長12.41%収益成長率13.11%株主資本利益率2.57%ネット・マージン0.14%前回の決算情報31 Dec 2025最近の業績更新お知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).分析記事 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.すべての更新を表示Recent updatesお知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, RomaniaNew Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.New Risk • Sep 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 38% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON91.0m market cap, or US$21.3m).New Risk • May 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RON78.2m market cap, or US$17.2m).Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025, at 12:30 E. Europe Standard Time. Location: at st. constantine hospital conference room in, brasov, 318 calea bucuresti, RomaniaNew Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON79.2m market cap, or US$17.4m).New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON81.8m market cap, or US$17.1m).分析記事 • Dec 06S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...New Risk • Sep 06New major risk - Revenue and earnings growthEarnings have declined by 2.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON91.5m market cap, or US$20.4m).New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (RON97.7m market cap, or US$21.4m).分析記事 • Dec 09Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Sep 23S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of ReturnFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Jun 01Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Mar 16Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Price Target Changed • Jul 26Price target decreased to RON0.23Down from RON0.38, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of RON0.22. Stock is down 7.5% over the past year.分析記事 • May 15S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 26S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Is New 90 Day High Low • Feb 09New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 11 November 2020. The Romanian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 6.0% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: RON0.24The company is up 8.0% from its price of RON0.22 on 15 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 8.0% over the same period.Is New 90 Day High Low • Dec 30New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 01 October 2020. The Romanian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 4.0% over the same period.分析記事 • Dec 23Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...分析記事 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...Is New 90 Day High Low • Nov 16New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 18 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 30 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.Is New 90 Day High Low • Oct 08New 90-day low: RON0.22The company is down 24% from its price of RON0.29 on 09 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 29New 90-day low: RON0.22The company is down 23% from its price of RON0.29 on 26 June 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period.収支内訳S.C. Ropharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BVB:RPH 収益、費用、利益 ( )RON Millions日付収益収益G+A経費研究開発費31 Dec 251,5442225030 Sep 251,4683224030 Jun 251,4300224031 Mar 251,377-1218031 Dec 241,323-2211030 Sep 241,255-1204030 Jun 241,1870198031 Mar 241,1544191031 Dec 231,1208185030 Sep 231,0999178030 Jun 231,07810171031 Mar 231,04010164031 Dec 221,0029157030 Sep 2297610153030 Jun 2295112149031 Mar 2291911146031 Dec 2188811143030 Sep 2185710138030 Jun 218269134031 Mar 218168129031 Dec 208067125030 Sep 207876122030 Jun 207695118031 Mar 207766115031 Dec 197848112030 Sep 197748114030 Jun 197649115031 Mar 1970011111031 Dec 1863612106030 Sep 1859612100030 Jun 185551294031 Mar 185451294031 Dec 175351294030 Sep 175321289030 Jun 175301385031 Mar 175191282031 Dec 165071079031 Dec 154719620質の高い収益: RPHは 高品質の収益 を持っています。利益率の向上: RPH過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: RPHの収益は過去 5 年間で年間35.2%減少しました。成長の加速: RPHは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: RPH昨年収益を上げたため、昨年の収益成長をConsumer Retailing業界 ( 24% ) と比較することは困難です。株主資本利益率高いROE: RPHの 自己資本利益率 ( 2.6% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-retailing 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 23:50終値2026/05/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋S.C. Ropharma S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026
Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.
Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).
分析記事 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...
Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.
お知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, Romania
New Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).
Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.
New Risk • Sep 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 38% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON91.0m market cap, or US$21.3m).
New Risk • May 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RON78.2m market cap, or US$17.2m).
Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).
お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025, at 12:30 E. Europe Standard Time. Location: at st. constantine hospital conference room in, brasov, 318 calea bucuresti, Romania
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON79.2m market cap, or US$17.4m).
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON81.8m market cap, or US$17.1m).
分析記事 • Dec 06S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
New Risk • Sep 06New major risk - Revenue and earnings growthEarnings have declined by 2.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON91.5m market cap, or US$20.4m).
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (RON97.7m market cap, or US$21.4m).
分析記事 • Dec 09Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Sep 23S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of ReturnFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Jun 01Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Mar 16Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Price Target Changed • Jul 26Price target decreased to RON0.23Down from RON0.38, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of RON0.22. Stock is down 7.5% over the past year.
分析記事 • May 15S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Mar 26S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Is New 90 Day High Low • Feb 09New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 11 November 2020. The Romanian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 6.0% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: RON0.24The company is up 8.0% from its price of RON0.22 on 15 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 8.0% over the same period.
Is New 90 Day High Low • Dec 30New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 01 October 2020. The Romanian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 4.0% over the same period.
分析記事 • Dec 23Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
分析記事 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...
Is New 90 Day High Low • Nov 16New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 18 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 30 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.
Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.
Is New 90 Day High Low • Oct 08New 90-day low: RON0.22The company is down 24% from its price of RON0.29 on 09 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 29New 90-day low: RON0.22The company is down 23% from its price of RON0.29 on 26 June 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period.